Stem definition | Drug id | CAS RN |
---|---|---|
1585 | 6893-02-3 |
Dose | Unit | Route |
---|---|---|
60 | mcg | O |
60 | mcg | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
May 8, 1956 | FDA | KING PHARMS R AND D |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Sensitisation | 338.27 | 14.28 | 83 | 12364 | 2285 | 56277335 |
Polycystic ovaries | 315.32 | 14.28 | 84 | 12363 | 3230 | 56276390 |
Ejection fraction | 275.07 | 14.28 | 66 | 12381 | 1649 | 56277971 |
Hypothyroidism | 262.26 | 14.28 | 140 | 12307 | 38056 | 56241564 |
Rhinitis allergic | 241.40 | 14.28 | 85 | 12362 | 8389 | 56271231 |
Blood test abnormal | 207.40 | 14.28 | 85 | 12362 | 12699 | 56266921 |
Carpal tunnel syndrome | 194.26 | 14.28 | 90 | 12357 | 18054 | 56261566 |
Sleep apnoea syndrome | 191.50 | 14.28 | 100 | 12347 | 25961 | 56253659 |
Sleep disorder due to a general medical condition | 191.46 | 14.28 | 73 | 12374 | 9017 | 56270603 |
Burning sensation | 147.55 | 14.28 | 106 | 12341 | 48590 | 56231030 |
Nephrectomy | 135.81 | 14.28 | 35 | 12412 | 1178 | 56278442 |
Cardiac disorder | 132.44 | 14.28 | 97 | 12350 | 45790 | 56233830 |
Fibromyalgia | 116.14 | 14.28 | 100 | 12347 | 59503 | 56220117 |
Renal disorder | 114.63 | 14.28 | 75 | 12372 | 29530 | 56250090 |
Gastrooesophageal reflux disease | 103.60 | 14.28 | 109 | 12338 | 83148 | 56196472 |
Asthma | 95.43 | 14.28 | 121 | 12326 | 112649 | 56166971 |
Ejection fraction abnormal | 91.08 | 14.28 | 25 | 12422 | 1075 | 56278545 |
Loss of personal independence in daily activities | 82.98 | 14.28 | 96 | 12351 | 81273 | 56198347 |
Therapeutic product effect incomplete | 74.64 | 14.28 | 104 | 12343 | 105927 | 56173693 |
Headache | 53.96 | 14.28 | 255 | 12192 | 558789 | 55720831 |
Hypertension | 48.61 | 14.28 | 141 | 12306 | 244137 | 56035483 |
Hyperthyroidism | 42.54 | 14.28 | 30 | 12417 | 13322 | 56266298 |
Urine chloride decreased | 39.65 | 14.28 | 8 | 12439 | 86 | 56279534 |
Suicidal ideation | 36.71 | 14.28 | 54 | 12393 | 57688 | 56221932 |
Wheezing | 36.41 | 14.28 | 62 | 12385 | 74964 | 56204656 |
Urine sodium decreased | 34.97 | 14.28 | 8 | 12439 | 161 | 56279459 |
Rheumatoid arthritis | 33.13 | 14.28 | 22 | 12425 | 382582 | 55897038 |
Weight increased | 31.60 | 14.28 | 117 | 12330 | 229586 | 56050034 |
Myopathy | 31.15 | 14.28 | 22 | 12425 | 9790 | 56269830 |
Palpitations | 30.74 | 14.28 | 68 | 12379 | 99604 | 56180016 |
Product substitution issue | 27.39 | 14.28 | 24 | 12423 | 14575 | 56265045 |
Thyroid function test abnormal | 24.69 | 14.28 | 13 | 12434 | 3420 | 56276200 |
Drug intolerance | 24.60 | 14.28 | 14 | 12433 | 264804 | 56014816 |
Systemic lupus erythematosus | 24.49 | 14.28 | 5 | 12442 | 180073 | 56099547 |
Glossodynia | 23.49 | 14.28 | 3 | 12444 | 152455 | 56127165 |
Feeling abnormal | 22.66 | 14.28 | 73 | 12374 | 133529 | 56146091 |
Arthropathy | 22.65 | 14.28 | 8 | 12439 | 200267 | 56079353 |
Acute kidney injury | 21.97 | 14.28 | 13 | 12434 | 240750 | 56038870 |
Blood thyroid stimulating hormone increased | 21.49 | 14.28 | 15 | 12432 | 6548 | 56273072 |
Wound | 20.75 | 14.28 | 3 | 12444 | 138801 | 56140819 |
Maternal exposure during pregnancy | 20.71 | 14.28 | 8 | 12439 | 189545 | 56090075 |
Tri-iodothyronine increased | 20.35 | 14.28 | 5 | 12442 | 138 | 56279482 |
Blood thyroid stimulating hormone abnormal | 18.72 | 14.28 | 7 | 12440 | 817 | 56278803 |
Nail growth abnormal | 18.02 | 14.28 | 6 | 12441 | 499 | 56279121 |
Thyroid cancer | 17.48 | 14.28 | 12 | 12435 | 5104 | 56274516 |
Peak expiratory flow rate decreased | 16.87 | 14.28 | 6 | 12441 | 608 | 56279012 |
Blood thyroid stimulating hormone decreased | 16.81 | 14.28 | 11 | 12436 | 4322 | 56275298 |
Product quality issue | 16.42 | 14.28 | 27 | 12420 | 31709 | 56247911 |
Thrombocytopenia | 16.17 | 14.28 | 5 | 12442 | 136219 | 56143401 |
Death | 16.10 | 14.28 | 32 | 12415 | 341394 | 55938226 |
Reaction to excipient | 15.72 | 14.28 | 7 | 12440 | 1277 | 56278343 |
Pre-existing condition improved | 15.59 | 14.28 | 13 | 12434 | 7385 | 56272235 |
Tri-iodothyronine decreased | 15.45 | 14.28 | 4 | 12443 | 137 | 56279483 |
Product dose omission issue | 15.17 | 14.28 | 87 | 12360 | 204666 | 56074954 |
Scar | 14.94 | 14.28 | 16 | 12431 | 12417 | 56267203 |
Hospitalisation | 14.58 | 14.28 | 43 | 12404 | 74957 | 56204663 |
General physical health deterioration | 14.38 | 14.28 | 10 | 12437 | 170000 | 56109620 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Performance enhancing product use | 50.50 | 23.37 | 8 | 1593 | 98 | 31695645 |
Rhythm idioventricular | 48.95 | 23.37 | 9 | 1592 | 277 | 31695466 |
Secondary hypogonadism | 48.73 | 23.37 | 9 | 1592 | 284 | 31695459 |
Thyrotoxic periodic paralysis | 43.52 | 23.37 | 7 | 1594 | 95 | 31695648 |
Autoimmune thyroiditis | 41.97 | 23.37 | 10 | 1591 | 1095 | 31694648 |
Loose associations | 39.36 | 23.37 | 6 | 1595 | 56 | 31695687 |
Glucose tolerance decreased | 37.91 | 23.37 | 6 | 1595 | 73 | 31695670 |
Diffuse vasculitis | 37.61 | 23.37 | 6 | 1595 | 77 | 31695666 |
Sinus arrest | 34.09 | 23.37 | 9 | 1592 | 1492 | 31694251 |
Feelings of worthlessness | 30.37 | 23.37 | 6 | 1595 | 272 | 31695471 |
Haematocrit increased | 27.51 | 23.37 | 8 | 1593 | 1889 | 31693854 |
Pressure of speech | 27.23 | 23.37 | 6 | 1595 | 464 | 31695279 |
Hyperthyroidism | 26.99 | 23.37 | 12 | 1589 | 9619 | 31686124 |
Insulin-like growth factor increased | 26.41 | 23.37 | 7 | 1594 | 1178 | 31694565 |
Blood prolactin decreased | 24.87 | 23.37 | 5 | 1596 | 248 | 31695495 |
Systolic hypertension | 24.43 | 23.37 | 5 | 1596 | 271 | 31695472 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Sensitisation | 353.84 | 15.77 | 81 | 10840 | 2392 | 70915131 |
Polycystic ovaries | 347.01 | 15.77 | 82 | 10839 | 2790 | 70914733 |
Ejection fraction | 286.12 | 15.77 | 64 | 10857 | 1698 | 70915825 |
Rhinitis allergic | 251.68 | 15.77 | 82 | 10839 | 9213 | 70908310 |
Hypothyroidism | 230.70 | 15.77 | 121 | 10800 | 45634 | 70871889 |
Carpal tunnel syndrome | 220.48 | 15.77 | 87 | 10834 | 16970 | 70900553 |
Blood test abnormal | 211.92 | 15.77 | 81 | 10840 | 14509 | 70903014 |
Sleep disorder due to a general medical condition | 195.76 | 15.77 | 70 | 10851 | 10406 | 70907117 |
Sleep apnoea syndrome | 177.74 | 15.77 | 91 | 10830 | 32622 | 70884901 |
Fibromyalgia | 160.72 | 15.77 | 97 | 10824 | 47777 | 70869746 |
Burning sensation | 159.36 | 15.77 | 100 | 10821 | 52770 | 70864753 |
Nephrectomy | 134.62 | 15.77 | 35 | 10886 | 1768 | 70915755 |
Cardiac disorder | 134.47 | 15.77 | 94 | 10827 | 59321 | 70858202 |
Gastrooesophageal reflux disease | 123.06 | 15.77 | 106 | 10815 | 90733 | 70826790 |
Renal disorder | 109.76 | 15.77 | 70 | 10851 | 37939 | 70879584 |
Asthma | 95.68 | 15.77 | 105 | 10816 | 120688 | 70796835 |
Loss of personal independence in daily activities | 91.22 | 15.77 | 87 | 10834 | 84823 | 70832700 |
Ejection fraction abnormal | 83.87 | 15.77 | 24 | 10897 | 1739 | 70915784 |
Therapeutic product effect incomplete | 82.68 | 15.77 | 97 | 10824 | 119785 | 70797738 |
Hyperthyroidism | 65.54 | 15.77 | 40 | 10881 | 20051 | 70897472 |
Headache | 61.20 | 15.77 | 212 | 10709 | 580193 | 70337330 |
Hypertension | 57.53 | 15.77 | 135 | 10786 | 295898 | 70621625 |
Urine chloride decreased | 41.43 | 15.77 | 8 | 10913 | 100 | 70917423 |
Performance enhancing product use | 40.39 | 15.77 | 8 | 10913 | 115 | 70917408 |
Wheezing | 36.99 | 15.77 | 58 | 10863 | 94112 | 70823411 |
Secondary hypogonadism | 36.87 | 15.77 | 9 | 10912 | 351 | 70917172 |
Thyrotoxic periodic paralysis | 35.32 | 15.77 | 7 | 10914 | 101 | 70917422 |
Urine sodium decreased | 33.66 | 15.77 | 8 | 10913 | 278 | 70917245 |
Rhythm idioventricular | 33.45 | 15.77 | 9 | 10912 | 519 | 70917004 |
Loose associations | 32.39 | 15.77 | 6 | 10915 | 59 | 70917464 |
Glucose tolerance decreased | 31.00 | 15.77 | 6 | 10915 | 76 | 70917447 |
Tri-iodothyronine increased | 29.98 | 15.77 | 7 | 10914 | 225 | 70917298 |
Insulin-like growth factor increased | 29.95 | 15.77 | 11 | 10910 | 1760 | 70915763 |
Diffuse vasculitis | 28.92 | 15.77 | 6 | 10915 | 110 | 70917413 |
Suicidal ideation | 27.51 | 15.77 | 43 | 10878 | 69553 | 70847970 |
Blood thyroid stimulating hormone decreased | 26.24 | 15.77 | 14 | 10907 | 5440 | 70912083 |
Myopathy | 25.72 | 15.77 | 22 | 10899 | 18590 | 70898933 |
Weight increased | 24.08 | 15.77 | 87 | 10834 | 242244 | 70675279 |
Thrombocytopenia | 21.88 | 15.77 | 5 | 10916 | 239105 | 70678418 |
Autoimmune thyroiditis | 21.75 | 15.77 | 11 | 10910 | 3831 | 70913692 |
Thyroid function test abnormal | 21.23 | 15.77 | 10 | 10911 | 2987 | 70914536 |
Blood thyroid stimulating hormone increased | 20.53 | 15.77 | 14 | 10907 | 8465 | 70909058 |
Feelings of worthlessness | 20.20 | 15.77 | 6 | 10915 | 495 | 70917028 |
Palpitations | 19.82 | 15.77 | 49 | 10872 | 110704 | 70806819 |
Feeling abnormal | 19.46 | 15.77 | 57 | 10864 | 142262 | 70775261 |
Product dose omission issue | 18.24 | 15.77 | 74 | 10847 | 217394 | 70700129 |
Product substitution issue | 18.03 | 15.77 | 18 | 10903 | 18495 | 70899028 |
Sinus arrest | 17.60 | 15.77 | 9 | 10912 | 3206 | 70914317 |
Immunoglobulins decreased | 17.47 | 15.77 | 7 | 10914 | 1417 | 70916106 |
Product preparation error | 17.39 | 15.77 | 10 | 10911 | 4492 | 70913031 |
Drug withdrawal syndrome | 16.98 | 15.77 | 23 | 10898 | 32692 | 70884831 |
Acute kidney injury | 16.45 | 15.77 | 30 | 10891 | 474594 | 70442929 |
Pyrexia | 16.42 | 15.77 | 44 | 10877 | 606908 | 70310615 |
Nail growth abnormal | 16.30 | 15.77 | 5 | 10916 | 460 | 70917063 |
Pressure of speech | 15.93 | 15.77 | 6 | 10915 | 1029 | 70916494 |
None
Source | Code | Description |
---|---|---|
ATC | H03AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
ATC | H03AA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
FDA CS | M0021977 | Triiodothyronine |
FDA EPC | N0000175946 | l-Triiodothyronine |
CHEBI has role | CHEBI:60311 | thyroid hormones |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Goiter | indication | 3716002 | DOID:12176 |
Myxedema coma | indication | 21263006 | |
Hypothyroidism | indication | 40930008 | DOID:1459 |
Myxedema | indication | 43153006 | DOID:11634 |
Congenital hypothyroidism | indication | 190268003 | DOID:0050328 |
Simple goiter | indication | 267369002 | |
Malignant tumor of thyroid gland | indication | 363478007 | DOID:1781 |
T3 Suppression for Thyroid Function Test | indication | ||
Mild Hypothyroidism | indication | ||
Diagnostic Test for Thyroid Dysfunction | indication | ||
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Thyrotoxic crisis | contraindication | 29028009 | DOID:12837 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Angina pectoris | contraindication | 194828000 | |
Osteopenia | contraindication | 312894000 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Disorder of coronary artery | contraindication | 414024009 |
Species | Use | Relation |
---|---|---|
Dogs | Hypothyroidism | Indication |
Product | Applicant | Ingredients |
---|---|---|
Cytobin Tablets | Zoetis Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.08 | acidic |
pKa2 | 8.12 | acidic |
pKa3 | 8.77 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thyroid hormone receptor alpha | Nuclear hormone receptor | AGONIST | Kd | 10.24 | CHEMBL | CHEMBL | |||
Thyroid hormone receptor beta | Nuclear hormone receptor | AGONIST | Ki | 10.10 | CHEMBL | CHEMBL | |||
Adenosine receptor A1 | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | EC50 | 6.30 | WOMBAT-PK | |||||
Prothrombin | Enzyme | EC50 | 8.92 | CHEMBL | |||||
Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | Kd | 6.15 | CHEMBL | |||||
Proliferating cell nuclear antigen | Nuclear other | IC50 | 5.44 | CHEMBL | |||||
THAP domain-containing protein 1 | Unclassified | EC50 | 9 | WOMBAT-PK | |||||
GABA-A receptor; anion channel | Ion channel | IC50 | 4.64 | CHEMBL | |||||
Thyroid hormone receptor beta | Transcription factor | IC50 | 8.74 | CHEMBL | |||||
GABA-A receptor; anion channel | Ion channel | EC50 | 5.15 | CHEMBL |
ID | Source |
---|---|
4022167 | VUID |
N0000020173 | NUI |
D01011 | KEGG_DRUG |
55-06-1 | SECONDARY_CAS_RN |
4018002 | VANDF |
4022167 | VANDF |
C0041014 | UMLSCUI |
CHEBI:18258 | CHEBI |
T3 | PDB_CHEM_ID |
CHEMBL1544 | ChEMBL_ID |
CHEMBL1201119 | ChEMBL_ID |
D014284 | MESH_DESCRIPTOR_UI |
DB00279 | DRUGBANK_ID |
2634 | IUPHAR_LIGAND_ID |
653 | INN_ID |
06LU7C9H1V | UNII |
5920 | PUBCHEM_CID |
10814 | RXNORM |
1964 | MMSL |
4982 | MMSL |
d00658 | MMSL |
002133 | NDDF |
004882 | NDDF |
126204001 | SNOMEDCT_US |
350358003 | SNOMEDCT_US |
61275002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2178 | TABLET | 25 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2179 | TABLET | 5 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2180 | TABLET | 50 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-303 | TABLET | 50 1 | ORAL | ANDA | 13 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-166 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-167 | TABLET | 25 ug | ORAL | ANDA | 24 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-168 | TABLET | 50 ug | ORAL | ANDA | 24 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-964 | TABLET | 5 ug | ORAL | ANDA | 25 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0151 | INJECTION, SOLUTION | 10 ug | INTRAVENOUS | ANDA | 25 sections |
Triostat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-120 | INJECTION | 10 ug | INTRAVENOUS | NDA | 25 sections |
NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-331 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-331 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-417 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-418 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-419 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-018 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-019 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-020 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-884 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-884 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45865-566 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3131 | TABLET | 5 ug | ORAL | ANDA | 27 sections |